DWTX vs. QTTB, BIVI, PLUR, SNYR, BFRG, IXHL, RLYB, PMN, CVM, and MRNS
Should you be buying Dogwood Therapeutics stock or one of its competitors? The main competitors of Dogwood Therapeutics include Q32 Bio (QTTB), BioVie (BIVI), Pluri (PLUR), Synergy CHC Corp. (Uplisting) (SNYR), Bullfrog AI (BFRG), Incannex Healthcare (IXHL), Rallybio (RLYB), ProMIS Neurosciences (PMN), CEL-SCI (CVM), and Marinus Pharmaceuticals (MRNS). These companies are all part of the "pharmaceutical products" industry.
Dogwood Therapeutics vs.
Dogwood Therapeutics (NASDAQ:DWTX) and Q32 Bio (NASDAQ:QTTB) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, community ranking, risk, dividends, earnings, valuation, media sentiment, profitability and analyst recommendations.
9.1% of Dogwood Therapeutics shares are held by institutional investors. Comparatively, 31.3% of Q32 Bio shares are held by institutional investors. 12.2% of Dogwood Therapeutics shares are held by company insiders. Comparatively, 16.1% of Q32 Bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Q32 Bio has a consensus target price of $24.86, suggesting a potential upside of 867.20%. Given Q32 Bio's stronger consensus rating and higher possible upside, analysts clearly believe Q32 Bio is more favorable than Dogwood Therapeutics.
Q32 Bio received 12 more outperform votes than Dogwood Therapeutics when rated by MarketBeat users.
Q32 Bio's return on equity of -146.18% beat Dogwood Therapeutics' return on equity.
Dogwood Therapeutics has a beta of 1.92, indicating that its share price is 92% more volatile than the S&P 500. Comparatively, Q32 Bio has a beta of -0.32, indicating that its share price is 132% less volatile than the S&P 500.
In the previous week, Q32 Bio's average media sentiment score of 0.79 beat Dogwood Therapeutics' score of 0.00 indicating that Q32 Bio is being referred to more favorably in the news media.
Dogwood Therapeutics has higher earnings, but lower revenue than Q32 Bio. Dogwood Therapeutics is trading at a lower price-to-earnings ratio than Q32 Bio, indicating that it is currently the more affordable of the two stocks.
Summary
Q32 Bio beats Dogwood Therapeutics on 11 of the 14 factors compared between the two stocks.
Get Dogwood Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for DWTX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Dogwood Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:DWTX) was last updated on 2/22/2025 by MarketBeat.com Staff
